Sugi Predict

Sugi Predict / Compounds / SCHEMBL22729409

SCHEMBL22729409

SCHEMBL22729409

Cc1cnc(Cl)c(C=O)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RECQL P46063 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ AXL P30530 1/20 0.35
▸ PRKCI P41743 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ AOX1 Q06278 1/20 0.33
▸ HSP90AA1 P07900 2/20 0.33
▸ HSP90AB1 P08238 1/20 0.33
▸ MPI P34949 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30082527 1.00 KDM4E (0.38) KDM4EMAPTRECQLNPSR1AXL
Pyridine SCHEMBL21226522 0.88 KDM4E (0.35) KDM4EMAPTRECQLNPSR1
SCHEMBL25847966 0.80 NOS3 (0.36) KDM4EMAPTRECQLNPSR1AXL
SCHEMBL20089295 0.78 ALDH1A1 (0.39) KDM4EMAPTRECQLNPSR1ALDH1A1
SCHEMBL8548155 0.77 ALDH1A1 (0.33) KDM4EMAPTCYP1A2CYP3A4CYP2D6
SCHEMBL22716205 0.76 KDM4E (0.33) KDM4EMAPTRECQLNPSR1CYP1A2
SCHEMBL31447380 0.75 POLB (0.35) ALDH1A1MEN1KMT2ATDP1
SCHEMBL25288597 0.75 NFE2L2 (0.37) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL14620918 0.72 KDM4E (0.39) KDM4EMAPTRECQLNPSR1CYP1A2
SCHEMBL27694985 0.72 AXL (0.42) AXLPRKCICYP3A4ALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289830-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2025-09-18 — — US disclosed
US-12351591-B2 KRas inhibitors ELI LILLY AND COMPANY (US) 2025-07-08 — — US disclosed
US-20240368193-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-11-07 — — US disclosed
US-20240254138-A1 TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-08-01 — — US disclosed
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-29 — — US disclosed
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2024-02-29 — — US disclosed
US-20240043451-A1 KRAS INHIBITORS ELI LILLY AND COMPANY 2024-02-08 — — US disclosed
EP-4305040-A1 TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS JANSSEN Pharmaceutica NV (BE) 2024-01-17 — — EP disclosed
US-20230365507-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2023-11-16 — — US disclosed
CN-116940577-A Tricyclic pyridines as cyclin dependent kinase 7 (CDK 7) inhibitors 詹森药业有限公司 2023-10-24 — — CN disclosed
US-11708334-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-25 — — US disclosed
US-11708334-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-25 — — US disclosed
US-11702391-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-18 — — US disclosed
US-11702391-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. (US) 2023-07-18 — — US disclosed
US-20230051130-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2023-02-16 — — US disclosed
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 — — US disclosed
WO-2022189387-A1 TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-09-15 — — WO disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 — — US disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708334-B2 Inhibitors of NLRP3 inflammasome NLRP3, NLRP1, PYCARD KDM4E 2856/4885MAPT 621/4885RECQL 848/4885
US-20210087186-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC KDM4E 1315/4885MAPT 356/4885RECQL 3977/4885
US-20240254138-A1 TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS CDK7, CDK2, CCNK KDM4E 924/4885MAPT 2285/4885RECQL 451/4885
US-20240067610-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 KDM4E 3223/4885MAPT 432/4885RECQL 685/4885
US-20240043451-A1 KRAS INHIBITORS KRAS, NRAS, HRAS KDM4E 2640/4885MAPT 4564/4885RECQL 177/4885
US-12351591-B2 KRas inhibitors KRAS, NRAS, HRAS KDM4E 2640/4885MAPT 4564/4885RECQL 177/4885
US-11702391-B2 Inhibitors of NLRP3 inflammasome NLRP3, CASP1, PYCARD KDM4E 3469/4885MAPT 613/4885RECQL 531/4885
US-20240368193-A1 KRAS INHIBITORS KRAS, NRAS, HRAS KDM4E 2107/4885MAPT 4453/4885RECQL 210/4885
US-20250289830-A1 KRAS INHIBITORS KRAS, NRAS, HRAS KDM4E 2640/4885MAPT 4564/4885RECQL 177/4885
US-20230051130-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 KDM4E 3223/4885MAPT 432/4885RECQL 685/4885
US-20230365507-A1 INHIBITORS OF NLRP3 INFLAMMASOME NLRP3, PYCARD, CASP1 KDM4E 3223/4885MAPT 432/4885RECQL 685/4885
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC KDM4E 1270/4885MAPT 364/4885RECQL 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.